Carvykti denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Carvykti as Duplicate Therapy

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy approved for certain patients with relapsed or refractory multiple myeloma. A "duplicate therapy" denial from Aetna typically occurs when another CAR-T therapy or cellular immunotherapy is already authorized or recently administered, and Aetna's system flags the new request as redundant. Because CAR-T therapies involve distinct manufacturing processes, target different antigens, and are not clinically interchangeable, this denial is almost always based on an administrative or coding error rather than a genuine clinical equivalence determination.

## Why This Denial Is Appealable

Carvykti targets BCMA (B-cell maturation antigen) via a specific construct that is distinct from other therapies in terms of manufacturing, mechanism, and approved indication. If the prior therapy Aetna identified as a "duplicate" is a different product — even another CAR-T — your oncologist can document that the therapies are not clinically equivalent and that the prior therapy either failed, was not administered, or addressed a different clinical situation. Additionally, if this is a first-time CAR-T authorization and the duplicate flag is purely an administrative error, the fix may be as simple as a corrected claim or a brief clarification letter.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 or state law, you have the right to a full-and-fair internal review. File within the timeline stated in your denial letter.
• External review: Under ACA §2719, after exhausting internal review you may request independent external review by an accredited IRO, typically within four months of the final internal denial.
• Expedited review: Given the serious nature of relapsed/refractory multiple myeloma, request expedited external review simultaneously with your internal appeal for a 72-hour determination.

## Documentation to Gather

• Prior therapy records: A complete treatment history for multiple myeloma, including all prior lines of therapy, with dates, regimens (by name as documented in the chart), and response assessments. This establishes what was actually administered and what was not.
• Product distinction documentation: A letter from your hematologist-oncologist explaining that Carvykti is a distinct product from any therapy Aetna has identified as a duplicate, and that the two are not clinically interchangeable.
• Diagnosis and disease-status records: Bone marrow biopsy results, response assessment labs, imaging, and clinic notes documenting current disease status and the basis for the Carvykti recommendation.
• FDA label reference: Your oncologist should reference Carvykti's FDA-approved indication and confirm your patient meets the indication criteria as stated in the approved prescribing information (without citing specific numeric thresholds — direct Aetna to verify those in the label).

## Criteria-Mapping Structure

Request Aetna's clinical policy for Carvykti and the specific basis for the duplicate-therapy flag (ask which prior authorization or claim Aetna believes is duplicative). Build a response table: left column identifies each duplicate-therapy criterion or the specific prior therapy Aetna cited; right column provides the documentary rebuttal — either showing the prior therapy is a distinct product, was not actually administered, or failed and is not a current active authorization. A concise, product-specific rebuttal letter from the treating oncologist is typically the most effective instrument for reversing this category of denial.